Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation Application Cleared for the Phase...

Related Keywords

United Kingdom ,Cambridge ,Cambridgeshire ,Dan Budwick ,John Evans ,Holly Manning ,Beam Therapeutics Inc ,Nasdaq ,Healthcare Products Regulatory Agency ,Strategic Communications ,Research Development Rd Expenses ,Exchange Commission ,Dosing Completed ,Sentinel Cohort ,Severe Sickle Cell Disease ,Expansion Cohort ,Trial Authorisation ,Application Cleared ,First Half ,New Drug ,First Quarter ,Cash Equivalents ,Marketable Securities ,Cash Runway Expected ,Support Operating Plans ,Engineered Stem Cell Antibody Paired Evasion ,Private Securities Litigation Reform Act ,Annual Report ,Consolidated Balance Sheet Data ,Consolidated Statement ,Months Ended March ,Markets ,